Biotechnology company Dance Biopharm Holdings Inc reported on Tuesday the completion of the acquisition of Harmony Biopharm Limited, the holder of its Dance-501 Asia license, from Harmony Plus Holdings Limited, an affiliate of Harmony Asset Management Group.
As part of a consulting / advisory agreement, Harmony will continue to advise Dance for the development of Dance-501 insulin product in China
Under the terms of the agreement, Dance will compensate Harmony with a combination of stock and a percentage of future revenues on sales of Dance-501 in China.
According to the company, Dance-501 consists of a high purity liquid formulation of recombinant human insulin stored in a dispenser for administration with a small handheld electronic inhaler. The electronic inhaler utilizes a patented vibrating mesh technology, designed to produce consistently sized particles of liquid insulin in the form of a soft mist, allowing the efficient and consistent delivery of insulin into the lungs in a few breaths.
Harmony and Dongbao, the top Chinese insulin manufacturer and marketer in China, were responsible for the development of a regulatory pathway with the Chinese FDA that calls for China to be part of a global Phase 3 programme that would enable the same regulatory documents to be used in the US, EU and China. This obviates the need for a "China alone" study and greatly facilitates bringing the product to market more efficiently. Dance-501 has not yet been approved by any regulatory authority.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva